GOODWILL AND OTHER INTANGIBLE ASSETS (Narrative) (Details)	3 Months Ended				12 Months Ended
	Sep. 30, 2019 USD ($)	Jun. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Dec. 31, 2019 USD ($) reporting_unit	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Goodwill [Line Items]
Number of reporting units | reporting_unit					3
Goodwill, impairment	$ 0
Impairment charge					$ 5,764,000	$ 4,941,000	$ 3,290,000
Amortization					72,800,000	71,600,000	52,800,000
Expected annual amortization expense, 2020					74,600,000
Expected annual amortization expense, 2021					64,100,000
Expected annual amortization expense, 2022					60,600,000
Expected annual amortization expense, 2023					59,700,000
Expected annual amortization expense, 2024					58,900,000
Expected annual amortization expense, thereafter					547,700,000
Amortization of product technology					$ 45,800,000	50,400,000	$ 35,700,000
Codman
Goodwill [Line Items]
Impairment assessment, royalty rate	5.00%
Intangible assets, indefinite life, discount rate percentage	12.50%
Codman | Trade name
Goodwill [Line Items]
Impairment of intangible assets	$ 0
Metasurg | Orthopedics and Tissue Technologies
Goodwill [Line Items]
Impairment charge			$ 4,900,000
Impairment charge, out of period adjustment included in original impairment						$ 2,500,000
Tarsus | Orthopedics and Tissue Technologies
Goodwill [Line Items]
Impairment charge				$ 3,300,000
Contract Manufacturing Customer, Notified By FDA To Remove Product From Market | Private Label | Customer relationship
Goodwill [Line Items]
Impairment charge		$ 5,800,000
Minimum | Codman
Goodwill [Line Items]
Impairment assessment, tax rate	17.40%
Maximum | Codman
Goodwill [Line Items]
Impairment assessment, tax rate	20.70%